161 related articles for article (PubMed ID: 31891209)
1. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction.
Gentile F; Elmenoufy AH; Ciniero G; Jay D; Karimi-Busheri F; Barakat KH; Weinfeld M; West FG; Tuszynski JA
Chem Biol Drug Des; 2020 Apr; 95(4):460-471. PubMed ID: 31891209
[TBL] [Abstract][Full Text] [Related]
2. Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease.
Gentile F; Barakat KH; Tuszynski JA
Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29710850
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and in vitro cell-free/cell-based biological evaluations of novel ERCC1-XPF inhibitors targeting DNA repair pathway.
Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Mani RS; Ciniero G; Tuszynski JA; Weinfeld M; West FG
Eur J Med Chem; 2020 Oct; 204():112658. PubMed ID: 32738410
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
[TBL] [Abstract][Full Text] [Related]
5. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
Gentile F; Tuszynski JA; Barakat KH
J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
[TBL] [Abstract][Full Text] [Related]
6. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
[TBL] [Abstract][Full Text] [Related]
7. Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF.
Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Weilbeer C; Mani RS; Barakat KH; Tuszynski JA; Weinfeld M; West FG
J Med Chem; 2019 Sep; 62(17):7684-7696. PubMed ID: 31369707
[TBL] [Abstract][Full Text] [Related]
8. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells.
Jordheim LP; Barakat KH; Heinrich-Balard L; Matera EL; Cros-Perrial E; Bouledrak K; El Sabeh R; Perez-Pineiro R; Wishart DS; Cohen R; Tuszynski J; Dumontet C
Mol Pharmacol; 2013 Jul; 84(1):12-24. PubMed ID: 23580445
[TBL] [Abstract][Full Text] [Related]
10. Function and Interactions of ERCC1-XPF in DNA Damage Response.
Faridounnia M; Folkers GE; Boelens R
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563071
[TBL] [Abstract][Full Text] [Related]
11. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.
McNeil EM; Melton DW
Nucleic Acids Res; 2012 Nov; 40(20):9990-10004. PubMed ID: 22941649
[TBL] [Abstract][Full Text] [Related]
12. Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF.
Chapman TM; Gillen KJ; Wallace C; Lee MT; Bakrania P; Khurana P; Coombs PJ; Stennett L; Fox S; Bureau EA; Brownlees J; Melton DW; Saxty B
Bioorg Med Chem Lett; 2015 Oct; 25(19):4097-103. PubMed ID: 26318993
[TBL] [Abstract][Full Text] [Related]
13. Molecular docking and molecular dynamics study on the effect of ERCC1 deleterious polymorphisms in ERCC1-XPF heterodimer.
Priya Doss CG; Nagasundaram N
Appl Biochem Biotechnol; 2014 Feb; 172(3):1265-81. PubMed ID: 24158589
[TBL] [Abstract][Full Text] [Related]
14. Acetylation of XPF by TIP60 facilitates XPF-ERCC1 complex assembly and activation.
Wang J; He H; Chen B; Jiang G; Cao L; Jiang H; Zhang G; Chen J; Huang J; Yang B; Zhou C; Liu T
Nat Commun; 2020 Feb; 11(1):786. PubMed ID: 32034146
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
[TBL] [Abstract][Full Text] [Related]
16. Repair synthesis step involving ERCC1-XPF participates in DNA repair of the Top1-DNA damage complex.
Takahata C; Masuda Y; Takedachi A; Tanaka K; Iwai S; Kuraoka I
Carcinogenesis; 2015 Aug; 36(8):841-51. PubMed ID: 26025908
[TBL] [Abstract][Full Text] [Related]
17. DCAF7 is required for maintaining the cellular levels of ERCC1-XPF and nucleotide excision repair.
Kawara H; Akahori R; Wakasugi M; Sancar A; Matsunaga T
Biochem Biophys Res Commun; 2019 Oct; 519(1):204-210. PubMed ID: 31493872
[TBL] [Abstract][Full Text] [Related]
18. DNA structural elements required for ERCC1-XPF endonuclease activity.
de Laat WL; Appeldoorn E; Jaspers NG; Hoeijmakers JH
J Biol Chem; 1998 Apr; 273(14):7835-42. PubMed ID: 9525876
[TBL] [Abstract][Full Text] [Related]
19. Physical and functional interaction between the XPF/ERCC1 endonuclease and hRad52.
Motycka TA; Bessho T; Post SM; Sung P; Tomkinson AE
J Biol Chem; 2004 Apr; 279(14):13634-9. PubMed ID: 14734547
[TBL] [Abstract][Full Text] [Related]
20. Activity of individual ERCC1 and XPF subunits in DNA nucleotide excision repair.
Gaillard PHL; Wood RD
Nucleic Acids Res; 2001 Feb; 29(4):872-9. PubMed ID: 11160918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
